Roche gets USFDA approval of Xofluza to treat influenza in children
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
She joins Enveda from Gilead Sciences
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Based on a post hoc analysis, fewer required respiratory interventions
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Subscribe To Our Newsletter & Stay Updated